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“Nature is nowhere accustomed more openly to display her 
 secret mysteries than in cases where she shows tracings 
 of her workings apart from the beaten paths; nor is there 
 any better way to advance the proper practice of medicine 
 than to give our minds to the discovery of the usual law 
 of nature, by careful investigation of cases of rarer forms 
 of disease.” 
Dr William Harvey, 1657 
  
 
  
ABSTRACT 
Congenital disorders affect approximately 3-4% of all children and often cause chronic 
disabilities with significant impact on the lives of affected individuals and their families as 
well as on the health-care system. These disorders constitute a large and heterogeneous 
group of disorders with most of them being rare (prevalence <1/2000) and having an 
underlying genetic basis. Understanding of the molecular etiology and phenotypic spectrum 
has expanded during recent years. Over the past ten years, it has been shown that different 
types of causative genetic variants, such as single nucleotide variants, small indels or copy 
number variants, can be detected in many patients with congenital disorders. However, much 
remain to be explored concerning the spectrum of genetic variants and phenotypes associated 
to these disorders. 
The studies in the thesis have focused on determining the molecular etiology of rare 
congenital disorders and delineating the phenotypes associated with these disorders. 
In order to achieve this, phenotypic investigations combined with genetic screening through 
clinical array-CGH and whole exome sequencing, followed by a strategy for evaluation, 
were performed in selected families. Twenty families with parental kinship and children 
affected by presumed autosomal recessive disorders and one additional family with a de 
novo dominant disorder were included in the studies. By this approach, a molecular 
diagnosis could be determined in 15 out of 21 families. With the results from the studies, 
the gene PIGT was established as a novel disease gene, the genes TFG and KIAA1109 were 
confirmed as novel disease genes and additional candidate genes for congenital disorders 
were identified. Furthermore, the phenotypes for disorders associated with the genes 
MAN1B1, RIPK4 and FLVCR2 were expended and the spectrum of pathogenic variants in 
the gene SATB2 was broadened. 
The overall conclusions from the studies were that WES is a very powerful method for the 
identification of disease-causing variants in consanguineous families and that the diversity 
of AR diseases is enormous with many of the identified disorders being extremely rare. An 
additional conclusion is that a detailed phenotypic assessment is crucial for interpretation of 
data from large-scale genetic screening and for ascribing pathogenicity to the identified 
variants. Moreover, the full spectrum of genetic variants, including sequence alterations and 
CNVs, should be considered for the etiology of rare disorders.  
The results altogether add detail to the clinical presentations of the given disorders and 
expand the number of genes and genetic variants with a presumed or established causal 
association to congenital disorders. Ultimately, this may increase the chances to achieve a 
genetic diagnosis for future patients. 
  
  
LIST OF SCIENTIFIC PAPERS 
I. Malin Kvarnung, Daniel Nilsson, Anna Lindstrand, Christoph Korenke, 
Samuel Chiang, Elisabeth Blennow, Markus Bergmann, Tommy Stödberg, 
Outi Mäkitie, Britt-Marie Anderlid, Yenan T. Bryceson, Magnus 
Nordenskjöld, Ann Nordgren  
A Novel Intellectual Disability Syndrome Caused by GPI-anchor 
Deficiency due to Homozygous Mutations in PIGT 
Journal of Medical Genetics. 2013 Aug;50(8):521-8 
 
II. Agne Liedén, Malin Kvarnung, Daniel Nilsson, Ellika Sahlin, Elisabeth Syk 
Lundberg 
Intragenic Duplication - A Novel Causative Mechanism for SATB2-
associated Syndrome 
Am J Med Genet A. 2014 Dec;164A(12):3083-7 
 
III. Malin Kvarnung, Fulya Taylan, Daniel Nilsson, Margareta Albåge, Magnus 
Nordenskjöld, Britt-Marie Anderlid, Ann Nordgren, Elisabeth Syk Lundberg 
Mutations in FLVCR2 associated with Fowler syndrome and survival 
beyond infancy 
Clinical Genetics. 2015 Feb 10, Epub ahead of print 
 
IV. Malin Kvarnung, Fulya Taylan, Daniel Nilsson, Helena Malmgren, Kristina 
Lagerstedt-Robinson, Eva Holmberg, Anders Helander, Alejandra Cuevas 
Cid, Kerstin Sars Zimmer, Suzanne Marcus, Britt-Marie Anderlid, Magnus 
Nordenskjöld, Ann Nordgren, Elisabeth Syk Lundberg  
Whole exome sequencing in consanguineous families with rare disorders: 
High diagnostic yield and new disease gene identification 
Manuscript 
 
  
CONTENTS 
1	   INTRODUCTION .......................................................................................................... 7	  
1.1	   RARE DISORDERS ............................................................................................ 7	  
1.1.1	   Definitions ................................................................................................ 7	  
1.1.2	   Prevalence ................................................................................................ 7	  
1.1.3	   Etiology .................................................................................................... 9	  
1.1.4	   Clinical presentation .............................................................................. 11	  
1.2	   GENETIC VARIANTS ...................................................................................... 12	  
1.2.1	   Definitions .............................................................................................. 12	  
1.2.2	   Spectrum of genetic variants in rare disorders ...................................... 12	  
1.2.3	   Mechanisms underlying CNV formation .............................................. 13	  
1.2.4	   Normal variation in the human genome ................................................ 13	  
1.2.5	   Normal variants versus disease-causing variants .................................. 14	  
1.3	   AUTOSOMAL RECESSIVE DISORDERS AND CONSANGUINITY ........ 15	  
2	   AIMS ............................................................................................................................. 18	  
3	   MATERIAL AND METHODS ................................................................................... 19	  
3.1	   PATIENTS .......................................................................................................... 19	  
3.2	   METHODS ......................................................................................................... 19	  
3.2.1	   Outline of the studies ............................................................................. 19	  
3.2.2	   Array-CGH ............................................................................................. 20	  
3.2.3	   MLPA ..................................................................................................... 20	  
3.2.4	   MPS ........................................................................................................ 21	  
3.2.5	   Interpreting variants detected by genetic screening methods ............... 23	  
4	   RESULTS AND DISCUSSION ................................................................................... 25	  
4.1	   RARE DUPLICATION IN SPORADIC SYNDROMIC 
INTELLECTUAL DISABILITY ...................................................................... 25	  
4.2	   RARE DISORDERS IN CONSANGUINEOUS FAMILIES .......................... 26	  
4.2.1	   Overall results in the cohort ................................................................... 26	  
4.2.2	   PIGT – a novel disease gene associated to AR syndromic ID .............. 29	  
4.2.3	   Pathogenic variants in FLVCR2 are compatible with survival 
beyond infancy ....................................................................................... 30	  
5	   CONCLUDING REMARKS ....................................................................................... 31	  
6	   FUTURE PERSPECTIVES ......................................................................................... 32	  
7	   POPULÄRVETENSKAPLIG SAMMANFATTNING .............................................. 36	  
8	   REFERENCES .............................................................................................................. 39	  
 
  
  
LIST OF ABBREVIATIONS 
AD 
AR 
bp 
CADD 
CGH 
CNV 
dbSNP 
 
DDD 
DECIPHER 
 
DGV 
DNA 
ds 
ExAc 
FADS 
FoSTeS 
GPI 
HGMD 
HPO 
HR 
HSP 
ID 
indel 
kb 
LCR 
MIM 
MLPA 
MMBIR 
MMEJ 
Autosomal Dominant 
Autosomal Recessive 
basepair 
Combined Annotation Dependent Depletion 
Comparative Genomic Hybridization 
Copy Number Variant 
database of Single Nucleotide Polymorphism (until 2011) 
database of Short Genetic Variation (from 2011) 
Deciphering Developmental Disorders 
DatabasE of genomiC varIation and Phenotype in Humans 
using Ensembl Resources 
Database of Genomic Variants 
DeoxyriboNucleic Acid 
double stranded 
Exome Aggregation Consortium 
Fetal Akinesia Deformation Sequence 
Fork-Stalling and Template Switching 
Glycosyl-Phosphatidyl-Inositol 
Human Gene Mutation Database 
Human Phenotype Ontology 
Homologous Recombination 
Hereditary Spastic Paraplegia 
Intellectual Disability 
insertion and/or deletion 
kilobase (1000 basepairs) 
Low Copy Repeat 
Mendelian Inheritance in Man 
Multiplex Ligation-dependent Probe Amplification 
Microhomology-Mediated Break Induced Replication 
Microhomology-Mediated End Joining 
  
MPS 
MRI 
NAHR 
NGS 
NHEJ 
OFC 
OMIM 
PCR 
PGD 
RNA 
Massive Parallel Sequencing 
Magnetic Resonance Imaging 
Non-Allelic Homologous Recombination 
Next Generation Sequencing 
Non-Homologous End Joining  
Occipito-Frontal Circumference 
Online Mendelian Inheritance in Man 
Polymerase Chain Reaction 
Preimplantation Genetic Diagnosis 
RiboNucleic Acid 
SNV 
Ss 
Single Nucleotide Variant 
single stranded 
SV 
UPD 
Structural Variant 
UniParental Disomy 
WES 
WGS 
XL 
Whole Exome Sequencing 
Whole Genome Sequencing 
X-linked 

  7 
1 INTRODUCTION 
Congenital or early onset disorders affect approximately 3-4% of all children and often cause 
chronic disabilities with significant impact on the lives of affected individuals and their 
families as well as on the health-care system. These disorders constitute a large and 
heterogeneous group of disorders with most of them being rare. Our understanding of the 
etiology and phenotypic spectrum of these disorders has expanded dramatically during recent 
years. Through genomic screening methods, it has been shown that the etiology is genetic in 
the majority of the patients and that the phenotypic spectrum often is larger than previously 
believed. 
Understanding these disorders is important and has direct clinical implications as it increases 
the chances of achieving an etiological diagnosis for patients with rare disorders, which in 
turn enables accurate genetic counseling and prenatal diagnostics as well as counseling 
regarding prognosis and, in some cases, treatment options. Furthermore, knowledge about the 
molecular etiology may open up for studies regarding treatment for some of these disorders. 
Despite recent years’ advances in the field, much remain to be explored concerning the full 
spectrum of genetic variants and phenotypes of these disorders. 
 
1.1 RARE DISORDERS 
1.1.1 Definitions 
The term “rare disorders” is widely used for disorders or diseases that affect few people – as 
opposed to the more common disorders or diseases, like diabetes, depression or 
cardiovascular disease, that affect many people. There are currently two definitions or cut-off 
levels regarding what should be considered as rare in this context; 
• In Europe, a disease or disorder is defined as rare when it affects fewer than 1 in 
2000.1 
• In the USA, a disease or disorder is defined as rare when it affects fewer than 
200,000 Americans at any given time.2 Considering a population of 319 million 
people in the USA, this definition can be translated into a disease or disorder that 
affects fewer than approximately 1 in 1600. 
The terms disorder and disease will be regarded as synonyms and used interchangeably in 
the text. 
1.1.2 Prevalence 
Despite the rarity of these disorders, the total number of people affected is large. It is 
estimated that a rare disease affects one person out of 15 and half of them are children.3, 4 
These figures are clearly in line with the commonly given incidence figure of 3-4% for 
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congenital or early onset disorders, which indicate that most of these disorders are rare. 
The high total prevalence is explained by the large number of rare disorders, which equals 
nearly 10,000.5, 6 Each individual disorder is rare, but when considered as a group, rare 
disorders are common. 
The prevalence distribution within the group of rare disorders is skewed. A few of these 
disorders are relatively common with prevalence above 1/20,000, while the vast majority of 
the disorders are very rare (Figure 1).7 It has been estimated that 80% of all rare disease 
patients are affected by approximately 350 rare diseases8, while the rest of the patients are 
affected by a plethora of very rare disorders. At the extreme end, there are disorders that 
have been described only in one or a few patients or families. 
 
Figure 1. Prevalence of different rare diseases 
Based on data from Orphanet report series, Rare diseases collection, July 20157 with permission from 
the publisher. 
For some disorders, the prevalence rates are highly variable between different populations 
and geographical regions. These differences can be due to factors that are either genetic or 
environmental. Examples on the latter are rare infections or exposure to harmful substances 
that are more prevalent in certain regions. Regarding genetic factors, there is a variation 
between populations in the prevalence and inheritance of certain genetic variants. The 
mechanisms behind this variation are several. One mechanism is limitation of the 
population size where individuals marry and reproduce within the community, either due to 
geographical boundaries or because of traditions that encourage marriage within the ethnic 
group, social class, religious group etc. A restriction in population size allows for the 
enrichment of potentially harmful genetic variants due to a founder effect that in turn 
increases the risk for disease. This may be exemplified by certain disorders, such as Salla 
disease that is more common in regions of Finland9 and Ellis van-Creveld syndrome that is 
more common in parts of the Amish population10. Another mechanism is natural selection 
for specific, potentially disease-causing, variants in certain geographical regions. This is 
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well known for the group of disorders called hemoglobinopathies, which include sickle-cell 
anemia and thalassemia. These disorders are historically rare in the European Union and the 
USA, while prevalence in endemic malaria regions reaches >1/100. Heterozygous carriers 
of these autosomal recessive disorders are protected against severe malaria and therefore 
the carrier status is favored in the population, with the drawback of an increased prevalence 
of hemoglobinopathies.11 A third mechanism that leads to variable disease prevalence is a 
difference in the rate of consanguineous marriages between different populations and 
regions. This will be discussed in more detail in chapter 1.3.  
1.1.3 Etiology 
Most of the rare disorders have a genetic basis, while others have non-genetic causes such 
as infections, auto-immunity and environmental factors. For a proportion of the disorders, 
the etiology is still unknown.4 
During the course over the last 25 years there has been enormous advances in deciphering 
the etiology of rare genetic disorders, which is reflected in the increasing number of known 
disease genes and disease-causing chromosomal aberrations as well as in the number of 
diseases or disorders with a known molecular cause.12-14 These data are recorded in the 
catalogue “Mendelian Inheritance in Man” (MIM), available online as “Online Mendelian 
Inheritance in Man” (OMIM), which lists more than 8000 phenotypes or diseases with a 
presumed genetic cause. Since 1990, the molecular etiology of more than 4500 of these 
disorders has been identified and the number of known disease genes is 3075 as of December 
1, 2015 (Figure 2A).5, 15 Despite the enormous progress in recent years, the basis is still 
unknown for nearly half of the diseases. As seen in figure 2A, the number of disorders with a 
known etiology is larger than the number of disease genes, which indicates that variants in 
the same gene can cause several different disorders. An example of this is the ERCC5 gene, 
which is associated to three different disorders; xeroderma pigmentosum, Cockayne 
syndrome and cerebrooculofacioskeletal syndrome.16, 17 The other way around, the same 
phenotype may be caused by variants in different genes, which is the case in intellectual 
disability for example, where an extreme heterogeneity is seen.18, 19 (In OMIM, these are 
designated as separate disorders coupled to the causative gene or chromosomal aberration.) 
For disorders that have a known molecular cause, the inheritance pattern is autosomal 
recessive in about half of the cases, autosomal dominant in 43% and X-linked in 6% (Figure 
2B).5  
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Figure 2. Number of entries in MIM/OMIM over time and inheritance of genetic diseases 
A) Diagram showing the cumulative number of entries into MIM/OMIM regarding known disease 
genes, genetic diseases with a known molecular cause and total number of described diseases (with a 
presumed genetic etiology), over the last 30 years. B) Pie chart showing the inheritance patterns for 
diseases with a known molecular cause. Based on data from Antonarakis et al 200012, Peltonen et al 
200113, McKusick 200714, Amberger et al 201515 and OMIM5.  
Reviewing etiology from a patient perspective, there are no comprehensive studies on the 
detailed etiology in cohorts of unselected rare disorder patients. However, there are several 
studies on different subgroups, for example patients with intellectual disability and 
developmental disorders. This group is of particular interest considering the high 
prevalence of these symptoms among rare disease patients in general5 and also among the 
patients that have been studied in the thesis (see Clinical Presentation below). Recent 
studies indicate that up to 40% of ID patients, are affected by specific monogenic disorders. 
Most of these are autosomal dominant, while some are X-linked (5-10%) or autosomal 
recessive (2-4%). Another 20% of the patients are affected by disorders caused by deletions 
or duplications that span >500 bp of the genome, so called copy number variants (CNVs). 
In addition, 11% of the patients have larger chromosomal aberrations, including 
aneuploidies. The studies also show that for the vast majority of all patients with a genetic 
cause, the genetic variant is not inherited, but instead de novo in origin. (The few sporadic 
patients with inherited variants are those with AR disorders and approximately half of those 
with X-linked disorders.) The remainder of all patients, approximately 30-40%, suffer from 
disorders that are still of unknown etiology or due to non-genetic factors.18-22 These figures 
contrast to what was known on the etiology of intellectual disability ten to fifteen years ago 
when 80% of the patients were considered to be affected by a disorder of unknown origin 
or due to non-genetic factors (Figure 3).23  
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Figure 3. Established causes of intellectual disability in 2003 and 2015 
Based on data from Stevenson et al 200323, Gillisen et al 201421 and Vissers et al 201522.  
Taken together, the data from 2003 and 2015 illustrate the tremendous progress within this 
field, which has been enabled by the rapid advances in methodology; the introduction of 
microarrays and more recently massive parallel sequencing, during the same time period. 
The methodologies are discussed in more detail in chapter 3. 
1.1.4 Clinical presentation 
Rare genetic disorders are characterized by a broad diversity of symptoms and signs, 
ranging from mild features affecting only part of the body to severe manifestations 
involving multiple organ systems. The age of onset ranges from the prenatal period into late 
adulthood. The nervous system is commonly affected, resulting in symptoms such as 
intellectual disability, epilepsy, neuropsychiatric disorders and motor dysfunction. In 
OMIM, nearly half of the disorders with known etiology (47%) get listed when searching 
for disorders with “ID or epilepsy or neurologic features”.5 
The particular vulnerability of the nervous system may result from its dependence on many 
different proteins, within and outside the nervous system, for adequate formation and 
maintenance of complex structures and functions. Dependence on many proteins or genes 
for normal function implies a large target for genetic aberrations that may give rise to 
symptoms of disease. 
Phenotypes that have been of particular interest in the thesis are those of early onset severe 
disorders. These are often characterized by ID, usually in combination with other features 
such as additional neurologic symptoms, congenital anomalies and dysmorphic features. 
Some of the disorders do not have ID as a major phenotypic finding, but instead one or 
several of the non-ID features mentioned above as main characteristics. 
 
  12 
1.2 GENETIC VARIANTS 
1.2.1 Definitions 
The term “genetic variant” is used in this text for any alteration of the DNA-sequence or 
structure, when compared to a reference genome, regardless of its potential functional 
effect. 
The terms “pathogenic variant” and “disease-causing variant” are regarded as synonyms in 
the text, and defined as variants that cause overt disease in an individual. However, it 
should be noted that pathogenic variants will not always be disease-causing, for example a 
pathogenic variant in a recessive gene usually does not cause a phenotype in heterozygous 
carriers. Furthermore, the synonymous use of these terms is applicable only for disorders 
that are due to fully penetrant variants, which is the case for the disorders included in the 
thesis. 
The term “deleterious variant” is used for variants that are predicted to severely affect 
protein function or expression, but not necessarily lead to disease.  
To avoid any confusion and in accordance with present recommendations24, the term 
“mutation” is not used in the text. (If by accident the term is used, it would refer to a 
pathogenic variant.) 
1.2.2 Spectrum of genetic variants in rare disorders 
As described previously, the etiology of rare disorders is diverse with different types of 
genetic variants and inheritance patterns. Traditionally, disease-causing genetic variants have 
been divided into chromosomal abnormalities, CNVs and monogenic variants with an overall 
focus on variants within or including genes. Division into these groups is still useful, but with 
advanced understanding of the mechanisms behind genetic disorders, the boundaries between 
the groups have become blurred. Genetic variants could be regarded more as a continuum 
ranging from small changes in the DNA sequence (single nucleotide variants or 
insertions/deletions of a few nucleotides) and repeat expansions to structural variants of 
varying sizes. Structural variants can be either balanced (inversions, translocations including 
insertions and complex rearrangements) or unbalanced with the latter also referred to as copy 
number variants (deletions or duplications).25 The size cut-off for what should be defined as a 
CNV was originally set at deletions or duplications >1 kb, but a more recent size definition is 
>50 bp.26 Most of the rare genetic disorders are caused by variants that reside either within a 
protein-coding gene or include one or several such genes, but in some cases the underlying 
defect may be localized to a non-coding region.27, 28 In addition, there are other types of 
variants such as uniparental disomy that cause some of the rare disorders. Focus in the studies 
included in the thesis lie on intragenic variants including sequence variants and CNVs. 
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1.2.3 Mechanisms underlying CNV formation 
The mechanisms behind CNV formation are complex and knowledge is continuing to evolve.  
Frequent and relatively well-characterized mechanisms include non-allelic homologous 
recombination (NAHR), non-homologous end joining (NHEJ) and fork-stalling and template 
switching (FoSTes)/micro-homology-mediated break induced replication (MMBIR).29 
Homologous recombination (HR) occurs naturally in cells; between homologous 
chromosomes in meiosis to increase genetic diversity and between or within chromatids to 
repair double-stranded (ds) DNA-breaks prior to mitosis.30 NAHR can occur in either of 
these settings, meiosis as well as in mitosis, and is the most common mechanism behind 
recurrent CNVs. In the case of NAHR, there is misaligning of two DNA-sequences due to the 
presence of multiple highly similar DNA-stretches such as low copy repeats (LCRs), 
followed by recombination.31 
NHEJ is another naturally occurring repair mechanism for ds DNA-breaks. Unlike HR, it can 
operate in the absence of a homologous template by “simply” joining the DNA ends. If there 
are two or more ds DNA breaks, errors that lead to CNVs may occur. Classical NHEJ is 
believed not be dependent on homology between the DNA-strands. However, presence of 
short homologous regions, i.e. micro-homology, between the ends of the DNA-strands may 
facilitate the repair process. NHEJ often results in small insertions or deletions of a few 
nucleotides at the ligation point (in addition to the larger CNVs that may be the result of 
faulty NHEJ).31, 32 A more recently described mechanism, which is a variant of NHEJ, is the 
micro-homology-mediated end joining (MMEJ), which relies on a different set of repair 
proteins and on the presence of micro-homology.33 The prevalence of MMEJ in humans 
remain to be elucidated. 
Lastly, FoSTes/MMBIR is a mechanism that may occur during DNA replication due to 
stalling of the replication fork. One of the newly synthesized single strands may detach 
from the template, alternatively, the fork collapses and one of the strands breaks resulting in 
a “lose end” ds-DNA. The single-stranded (ss) DNA or an overhanging part of the ds-DNA 
may thereupon anneal to another template with micro-homology to the original template 
and continue to replicate. This may happen one or several times before returning to the 
original template.29, 34 
1.2.4 Normal variation in the human genome 
Inter-individual variation 
The different types of genetic variants that may cause rare disorders are outlined above in 
chapter 1.2.2. During the past ten to fifteen years, it has become increasingly clear that the 
same types of genetic variants are present all over the genome in any human and account for 
normal inter-individual genetic variation.35-37 The genomes from two individuals are 98-99% 
similar, while the remainder differs between the two. A large study on human genetic 
variation estimates that the difference between the genome of one individual and a reference 
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genome is 0.1% due to SNVs, 1.2% due to CNV/indels and 0.3% due to inversions.38 These 
figures correlate to findings that individuals carry on average 3 million SNVs and more than 
1000 CNVs (>500 bp) when compared to a reference genome.39, 40 
Deleterious genetic variants in healthy individuals  
Recent studies have shown that the genome from a healthy individual may contain as many 
as 100 seemingly deleterious variants, mostly in a heterozygous state, but also some (0-20) 
bi-allelic variants.41, 42 There are several possible explanations for the absence of a disease 
phenotype despite these variants. It has been shown that many human genes are 
haplosufficient43, so for heterozygous variants, there may be sufficient expression from the 
wild type allele. Regarding bi-allelic variants, there may be residual protein function, 
compensation by similar genes/proteins, variants that only affect non-essential transcripts or 
variants in genes that are dispensable.42 
De novo variants 
Some of the variants that are seen in an individual have arisen de novo. All humans carry a 
number of SNVs that are not present in samples from the parents. The number is estimated at 
approximately 70 SNVs per individual genome44 or approximately one non-synonymous 
SNV per individual exome18. These figures correlate to the age of the father with an increase 
of 2 SNVs per year.45 De novo CNVs or indels are not as prevalent as de novo SNVs. Large 
de novo CNVs (>50 kb) occur in approximately one out of 50 individuals46 while smaller de 
novo variants (indels <50 bp) occur in all individuals at a rate of approximately 9 per 
individual genome44. 
1.2.5 Normal variants versus disease-causing variants 
To summarize the above paragraphs; each human genome contains millions of variants that 
are not present in a reference genome, many of these are seemingly deleterious (without 
strong phenotypic effects) and some of them are de novo variants. With this in mind, 
predicting the functional effect of a genetic variant is sometimes very challenging. The effect 
of a specific genetic variant and its impact on an individual’s health is determined by several 
factors such as genomic localization, size of the variant, nucleotides involved and more. 
Making a distinction between a disease-causing variant and a normal variant is one of the 
major challenges in human genetics today, both in research as well as in a clinical setting. 
Through the introduction of massive parallel sequencing techniques millions of genetic 
variants can be detected in a single individual, which requires a process for filtering and 
interpretation. This process and the methods used are discussed in chapter 3.2. 
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1.3 AUTOSOMAL RECESSIVE DISORDERS AND CONSANGUINITY 
The statistics on inheritance and etiology of rare disorders, as illustrated in figure 2B and 3, 
imply that the majority of rare disorders are inherited in an AR pattern, while only a minority 
of the patients have an AR disorder. This discrepancy indicates that there are numerous AR 
disorders that are, not only rare, but extremely rare with a very low prevalence for each 
disorder. Nevertheless, understanding the specific etiology of these disorders is highly 
relevant, as it increases the chances of achieving an etiological diagnosis for patients with AR 
disorders. Diagnosing these disorders is critical, since the recurrence risk is high (25%) and a 
specific diagnosis is a prerequisite for genetic counseling, prenatal diagnostics in future 
pregnancies, as well as for counseling issues regarding prognosis and, in some cases, 
treatment options. Understanding and diagnosing AR disorders is of particular importance for 
patients whose parents are consanguineous since the prevalence of AR disorders is increased 
in this subgroup of rare disease patients. The genetic basis for this increase and the recent 
advances in diagnosing AR disorders are discussed in more detail below. 
Consanguinity is defined as a union between two individuals who are related as second 
cousins or closer and is common in many parts of the world.47 Rare disorders are somewhat 
more prevalent in the offspring of consanguineous couples compared to the prevalence in 
an outbred population. For children born to parents that are first cousins, the estimated 
prevalence of a congenital or early onset disorder is 5-8%, which is approximately twice the 
prevalence seen in an outbred population. The observed increase is attributed to disorders 
that are inherited in an autosomal recessive pattern, which is a rare inheritance pattern in the 
general population (Figure 4).47-49 However, it is of importance to emphasize that despite the 
increased prevalence of AR disorders, the vast majority of children born to consanguineous 
parents are completely healthy. 
 
Figure 4. Prevalence and etiology of congenital disorders by parental relatedness 
Based on data from Bittles et al47, Hamamy et al48, Zlotogora et al49 and Powis et al50. 
The basis for an increased prevalence regarding AR disorders in the offspring of 
consanguineous couples is parental sharing of alleles that each has a low carrier frequency in 
the general population. The proportion of sharing depends on the degree of relation between 
two individuals. For example, first cousins share 1/8 of their genome, which implies that they 
will share the same allele at 1/4 of the loci. As for AR inheritance in general, the risk for 
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offspring of parents that carry the same allele (or different variants in the same gene) to 
inherit both these alleles is 1/4. Taken together, this means that the offspring of first cousin 
parents will be homozygous at 1/16 (1/4x1/4) of their genome. In the case where 
homozygosity is due to inheritance from one (or several) common ancestors the terms 
autozygosity or identity by descent may also be used. If a pathogenic variant resides within 
the autozygous regions, this may give rise to an AR disorder (Figure 5). 
 
Figure 5. Allele sharing in first cousins and autozygosity in the offspring 
A four-generation pedigree illustrating an individual (Z) born to parents that are first cousins (X and 
Y). Each vertical line next to the individuals illustrates the haploid genome of the individual. The 
colors represent the proportion of the genome that is inherited from the common ancestors in the first 
generation of the pedigree. X and Y share the same allele at 1/4 of the loci. (The probability that X 
and Y have the same color at a locus is one in four as illustrated by the four colors). Z is autozygous 
at 1/16 of the loci. (The probability that the maternal allele in a locus derive from the common 
ancestors is 1/2 as illustrated by half the haploid genome being colored. The probability that the 
paternal allele derive from the common ancestors is also 1/2. The probability that these alleles are the 
same is 1/4 as illustrated by the four colors. Altogether this equals 1/16). The lightning-symbol 
illustrates a pathogenic variant. 
Obviously, the majority of the alleles that are shared between first cousins do not harbor any 
disease-causing variants. The likelihood of carrying an autosomal recessive disease-causing 
variant is not different for an individual in a consanguineous marriage than for any person in 
the general population. The carrier rate for autosomal recessive disease-causing variants is 
estimated at 2-5 per individual.51 In one study by Bell et al., 437 recessive disease genes were 
sequenced in 104 healthy individuals and there were on average 2.8 (0-7) recessive 
deleterious variants per individual.52 From these findings, estimating the frequency of 
disease-causing variants in the complete genome would clearly result in higher figures. On 
the other hand, large scale sequencing studies find that healthy humans carry a number of 
seemingly deleterious recessive variants in a homozygous or compound heterozygous state, 
which suggest that not all seemingly deleterious variants result in an overt disease 
phenotype.41 Taken together, the estimate of each individual carrying 2-5 recessive 
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pathogenic variants seems rational and, interestingly, it correlates very well to early 
theoretical estimates.53 The recessive variants seen in healthy carriers are most frequently 
small sequence alterations. However, a study by Boone et al. show that approximately one 
out of seven individuals carry heterozygous CNVs affecting recessive disease genes.54 In 
summary, for children born to consanguineous parents, the combination of inter-parental 
allele-sharing and the fact that humans carry a number of AR disease-causing variants lead to 
an increased risk for bi-parental inheritance of such variants, which in turn may manifest as 
an AR disorder. 
Similar to what has been achieved in recent years when it comes to defining the etiology of 
rare disorders in general, there have been major advances in understanding the specific 
etiology of AR rare disorders, largely by studying consanguineous families. The first study on 
a large cohort of patients, by Najmabadi et al, took advantage of the massive parallel 
sequencing (MPS) technology (see methods 3.2.4) and identified the molecular etiology in 78 
out of 136 consanguineous families. Only in this study, 50 novel genes were identified and 
for the majority of the diagnosed families (73/78) the identified gene was unique to that 
family.55 These figures illustrate the extreme heterogeneity in AR rare disorders as well as the 
rapid pace of novel gene discovery made possible by the MPS technology. This method was 
applied also in a study of outbred families with multiple affected children and identified 
potential AR disease genes in 5 out of 20 families.56 Several recent studies on the etiology of 
AR disorders in cohorts of consanguineous families have been successful using MPS.57-62 In a 
clinical setting with an unselected group of patients, it is important to remark that, in addition 
to AR disorders, other etiologies should also be considered for children to consanguineous 
parents. A study of unselected consanguineous families analyzed with MPS in a clinical 
setting revealed AR inheritance in 62% of the cases with a monogenic etiology.50   
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2 AIMS 
The aims of the thesis were to: 
• Determine the specific etiology in patients with rare congenital disorders  
• Identify new disease genes in patients with rare congenital disorders  
• Delineate the phenotypes associated with these disorders 
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3 MATERIAL AND METHODS 
3.1 PATIENTS 
The patients included in the studies were referred to the Department of Clinical Genetics, 
Karolinska University Hospital in Stockholm, from 2008 through 2014 for assessment and 
investigation due to a clinical phenotype that raised suspicion of a rare congenital disorder 
with an underlying genetic etiology.  
All patients who had at least one sibling with the same phenotype, normal findings on clinical 
array-CGH and parental consanguinity were included for further investigations. In addition, 
one sporadic patient with a rare CNV on clinical array-CGH was included for further studies. 
Genomic DNA was extracted, using standard protocols, from blood samples from all patients 
as well as the unaffected siblings and parents. The patients further underwent thorough 
clinical examinations, including radiologic and biochemical investigations. 
The studies were approved by the Regional Ethics Committee in Stockholm and written 
informed consent was obtained from each participating individual or their legal guardians.  
 
3.2 METHODS 
3.2.1 Outline of the studies 
For the group of patients with consanguineous parents, an autosomal recessive rare disorder 
due to a homozygous genetic variant was hypothesized. DNA from all affected individuals as 
well as unaffected siblings and parents were analyzed with whole exome sequencing 
followed by a process of filtering, assessment and validation of the detected variants, 
including Sanger-sequencing of variants that were assessed as pathogenic or likely 
pathogenic. 
For the case with a rare CNV on array-CGH, further analyses with MLPA and mate-pair 
sequencing were performed in order to delineate the exact size and location of the CNV as 
well as to better understand the mechanism of formation. These data combined with detailed 
phenotype data were analyzed in determining the etiology of this rare disorder. 
The methods used and their resolution are illustrated in Figure 6. (Chromosome analysis is 
included for comparison.) 
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Figure 6. Resolution of different methods for detecting genetic variants 
 
3.2.2 Array-CGH 
Microarray-based comparative genomic hybridization (array-CGH) allows for a high-
resolution screening regarding DNA copy number variation, i.e. CNVs. The method is 
based on the comparison of test and reference genomic DNA samples that are labeled with 
two different fluorescent colors and hybridized to unique oligonucleotides (probes) 
positioned on a glass slide. The amount of test-DNA versus reference-DNA in each 
position is measured from the intensity of fluorescent color-signal and analyzed as a ratio 
between the two, the log2-ratio. Resolution is dependent on the number of probes. The type 
of array-CGH used for the studies was a 180K SurePrint G3 Human CGH oligonucleotide 
microarray (Agilent Technologies, Santa Clara, CA) with an average resolution of 
approximately 50 kb, performed at the Department of Clinical Genetics, Karolinska 
University Hospital. Regions with a minimum of three consecutive probes with aberrant 
log2 ratios (above 0.35 for duplications and below -0.65 for deletions) were considered for 
further analyses. 
3.2.3 MLPA 
Multiplex ligation-dependent probe amplification (MLPA)63 is another method to detect 
copy number variation. Unlike array-CGH, it is a targeted method that allows for the 
investigation of a limited number of genomic regions. The principle of MLPA is that for 
each locus of interest, two DNA oligonucleotides (probes) hybridize to their target 
sequences on the test DNA. If there is a perfect match, the two probes are ligated and 
subsequently amplified via a PCR reaction. The product from each probe-pair has a specific 
length (130-490 bp) and can thus be separated by electrophoresis and quantified. The 
amount of each PCR-product correlates to the amount of test DNA in that specific locus. 
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An algorithm for normalization within the test-DNA (via calculation of a ratio between the 
amount of PCR-products from each test-probe to the amount of PCR-products from 
control-probes that hybridize to sequences which are not subject to copy number variation) 
as well as between the test DNA and normal control DNA is applied to ensure stable and 
reliable results.  
3.2.4 MPS 
Massive parallel sequencing (MPS), also known as next generation sequencing (NGS) or 
high throughput sequencing, is a collective term for different technologies that all have in 
common the simultaneous sequencing of numerous genomic regions. The technology used 
in the thesis studies is sequencing by synthesis from Illumina (Illumina Inc, San Diego, CA, 
USA) based on reversible terminator chemistry.64 The process for detecting different types 
of genetic variants consists of four steps; (1) library preparation, (2) cluster generation, (3) 
sequencing and (4) data-processing including alignment to a reference sequence for final 
detection of the variants. An overview of the steps is illustrated in Figure 7. 
Library preparation starts with a random fragmentation of the DNA-sample and can then be 
performed in a number of manners with different types of data-handling and resulting 
output in the last step. For the studies in the thesis, whole-exome sequencing and, in one 
case, mate-pair sequencing have been applied. Library preparation for WES has the purpose 
of capturing all protein-coding exons in the genome (180.000 exons). The commercial 
Agilent SureSelect Human All Exon 50M kit (Agilent Technologies, Santa Clara, CA, 
USA) was used. This method is based on an in-solution hybridization of sample DNA to 
biotinylated RNA-oligonucleotides that are complementary to human exonic sequences. 
The RNA-DNA fragments are made magnetic by adding magnetic micro-beads covered 
with streptavidin that bind to biotin, whereupon magnetism may be used for capturing. 
Another type of library preparation is that for mate-pair sequencing. The purpose of this 
method is to create pairs of DNA-sequences that are thousands of bp apart, which is 
informative regarding genome structure and can be used for the detection of SVs. In order 
to achieve this, sample DNA-fragments as long as 2-5 kb are used. These are circularized 
and the ends are joined, followed by another round of fragmentation and purification that 
results in smaller pieces of DNA that correspond to the ends of the initial fragment. 
Notably, these pieces have an inverted orientation.  
Prior to sequencing, the DNA-fragments to be analyzed are bound to the surface of a lane in 
a flow cell and each fragment is amplified via bridge-PCR to create a cluster of identical 
DNA sequences that are all bound to the surface. The number of clusters/per lane is in the 
range of 100-200 million.  
Sequencing is performed using the DNA-fragments on the flowcell as templates and 
sequentially incorporating dye labeled nucleotides. Only one nucleotide at a time can be 
added due to a terminator linked to the nucleotide. After each addition, the fluorescent dye 
signal is imaged and the corresponding nucleotide is recorded. The terminator and dye is 
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then washed away, whereupon the cycle is repeated until the sequence of around 100 bp is 
complete. For paired-end sequencing, a second round of cluster generation and sequencing 
follows, which renders sequence data from the opposite end of the DNA-fragment.65 
The last step involves processing of all the data generated from sequencing. There are various 
programs for different parts of this process and for addressing different issues, such as the 
type of genetic variants to be detected (e.g. SNVs or SVs). In brief, the goal is to align the 
achieved sequences to a reference genome and detect the differences between the two. 
 
Figure 7. Overview of the steps in MPS using Illumina technology65 
The figure is a simplified overview of the steps in MPS using Illumina technology, leaving out a 
number of steps such as adapter-ligation, PCR-amplification and purification. For explanation of the 
different steps, please refer to the text. 
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3.2.5 Interpreting variants detected by genetic screening methods 
Genetic screening methods such as array-CGH or MPS detect numerous genetic variants in 
an individual. For most patients with a rare disorder, only one or a few variants are 
pathogenic (i.e. causative of the disease-phenotype). In order to identify the disease-causing 
variant(s), various measures for filtering, prioritization and evaluation are available, 
schematically shown in figure 8.66 Filtering and prioritization are facilitated by the use of 
databases and tools for predicting the functional effect of genetic variants. They are 
valuable also for evaluation of variants, which rely on manual assessment and sometimes 
additional experiments, based on the observed phenotype. 
 
Figure 8. Overview of the process for interpreting genetic variants detected by genomic screening 
 
Databases for genetic variants 
Great efforts have been made in creating useful databases with collections of normal variants 
and/or disease-causing variants to aid in the interpretation of variants identified in patients.  
Databases that collect disease-causing variants are for example DECIPHER67, which 
traditionally have focused on CNVs and the Human Gene Mutation Database (HGMD)68, 
whose main focus has been on SNVs. However, both databases now include different types 
of variants. Regarding normal variants, these are recorded in, for example, Database of 
Genomic Variants (DGV)26 with main focus on CNVs, and dbSNP69 or ExAc70, who both 
focus on SNVs. Recording of phenotype data in databases has become increasingly important 
for assisting in the interpretation of variants and assigning pathogenicity to variants. The 
comparison of phenotypes in different patients who have variants affecting the same gene or 
genes is highly informative in the process of assessing genetic variants. Many databases, such 
as DECIPHER, have included phenotype data in a standardized format based on the Human 
Phenotype Ontology (HPO).71 Other databases such as OMIM, include phenotype data in a 
less strict manner.  
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Tools for predicting the functional effect of genetic variants 
There are numerous tools for predicting pathogenicity of genetic variants. These programs 
use different algorithms and hence, the outcome may differ depending on program. For the 
thesis studies, different tools have been used with Combined Annotation Dependent 
Depletion (CADD)72 as the major one. It has the advantage of integrating a number of 
annotations to produce a combined score. The scaled CADD score relates the variant of 
interest to all possible theoretical variants in the genome resulting in log-scaled number. For 
example, a score of 20 means that the variant is in the top 1% of the most deleterious 
variants, a score of 30 in the top 0.1% etc. 
Evaluation and scoring of genetic variants 
After narrowing down the number of potential pathogenic variants by filtering and 
prioritization, manual evaluation of the remaining variants is possible. The number of 
variants to evaluate depends on filtering and cut-off level for prioritization. In the thesis, 
filtering on a minor allele frequency of 1% and segregation according to an autosomal 
recessive pattern was applied and all remaining variants, regardless of priority, were 
evaluated. The variants were evaluated with respect to their relevance for the observed 
disease phenotype with a resulting score (benign, likely benign, unknown significance, 
likely pathogenic or pathogenic). Notably, for a given variant these scores may be subject 
to change after achievement of results from additional investigations. In order to score a 
variant as pathogenic, the following criteria was used; (a) a phenotype that is identical or 
similar to previously described cases with pathogenic variants affecting the same gene and 
segregation in the family, in combination with either a variant that was previously reported 
as pathogenic or a non-sense/frame-shift variant or a variant with scaled CADD-score >20 
or (b) a variant in a novel gene with several lines of evidence for functional effects and 
causality. 
Evaluating the potential pathogenicity of a variant largely depend on the phenotype 
observed in the individual as well as in other members of the family. Comparison of the 
observed phenotype to other cases with variants affecting the same gene or genes in the 
same pathway is informative. Additional information on a gene level can be achieved by 
data on expression in the tissue of interest and functional assays in “knock-out” cell-lines or 
animal models. The latter may be used also for assessing the effect when introducing a 
specific genetic variant. Evaluation of the functional effect of a specific variant can 
likewise be performed by analyses in the individual itself, which can be considered as an 
extended phenotype characterization or molecular phenotyping. These analyses may also 
include family members as part of a segregation analysis (Figure 8).66 
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4 RESULTS AND DISCUSSION 
4.1 RARE DUPLICATION IN SPORADIC SYNDROMIC INTELLECTUAL 
DISABILITY 
(PAPER II) 
Array-CGH identified a small de novo duplication on chromosome 2 in a male patient with 
intellectual disability, speech and language impairment, cleft palate, malformed teeth, and 
oligodontia. The finding was confirmed with MLPA, which showed that the duplication 
included exon 5, 6 and 7 of the SATB2 gene. Further analysis with WGS using mate-pairs 
proved that the duplicated region (≈35 kb) was intragenic and arranged in tandem. Closer 
examination with Sanger-sequencing of the breakpoint junction revealed a 3 bp sequence of 
micro-homology shared between the distal and proximal breakpoints (Figure 9). 
 
Figure 9. Schematic illustration of the intragenic duplication in SATB2 
a) Results from array-CGH and MLPA showing probes consistent with duplication of exon 5-7. b) 
Reference gene c) Mate-pair sequencing reads from DNA-fragments that span the breakpoint junction 
in DNA from the patient (lower) showing an inverted (forward-reverse) mapping-orientation within 
the reference gene (upper) d) Illustration of the tandem duplication in the patient. e) Sanger-
sequencing of the break point junction in the patient showing that 3 basepairs (CAC) are common to 
the proximal and distal breakpoints, i.e. micro-homology between the regions. Adapted from figure 2 
in paper II. 
The findings of a direct tandem orientation of the duplication and micro-homology in the 
breakpoint junction were in line with recent studies showing the prevalent occurrence of 
these findings for duplications. Studies of rare, non-recurrent duplications show that 80-
90% are arranged in tandem. (The remaining duplications are part of complex 
rearrangements or due to an insertional translocation.)73 Furthermore, micro-homology (2-
70 bp) in breakpoint junctions of rare, non-recurrent, CNVs is a common finding seen in 
approximately 70-80% of these CNVs. The frequency is similar for deletions and 
duplications as well as for normal variants and pathogenic variants.74, 75 
The conclusions drawn from the genetic results in the patient were that, based on the 
finding of micro-homology, the most likely underlying mechanism of formation was either 
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a replication based mechanism (i.e. FoSTes/MMBIR) or NHEJ/MMEJ, which both depend 
on micro-homology (see chapter 1.2.3). Furthermore, the intragenic location of the 
duplication, strongly suggested a functional effect on the SATB2 protein. This conclusion 
was supported also from the phenotypic findings, which were very similar to the phenotype 
described in other cases with pathogenic SATB2 variants. At the time of the study, there 
were only six patients reported with deleterious variants in (and confined to) SATB2; two 
cases with SNVs and four cases with intragenic deletions.76-79 Our case was the first 
description of an intragenic SATB2 duplication. As of today, there are two additional 
reports of cases with intragenic duplications in the same gene (exon 3 and exon 4, 
respectively).80, 81 
With the introduction of MPS and screening of large cohorts of patients with rare disorders, 
variants in SATB2 have shown to be a prevalent cause of syndromic intellectual disability. 
Two recent large MPS screening studies have reported a total of 12 cases with de novo 
SNVs or small indels in SATB2.19, 82 In fact, SATB2 appeared as one of the top five 
causative genes in the large DDD-study, when reporting the findings in more than 1000 
children with developmental disorders.19 A distinct and recognizable phenotype has 
emerged over time and together with results from the recent MPS-studies, the phenotype is 
now further confirmed. All patients seem to have intellectual disability (often moderate-
severe), limited or absent speech and visible dental abnormalities (oligodontia, abnormal 
shape, crowding). Nearly all patients have cleft palate, a happy and jovial personality, 
micrognathia and distinct facial features. Osteopenia/osteoporosis is recorded in many 
patients. Seizures and abnormalities on MRI of the brain are rare, but can be part of the 
phenotype. Growth parameters including OFC are typically within the normal range. 
There are yet no phenotypic findings that can differentiate between patients with SNVs 
versus intragenic CNVs, suggesting that there is a common underlying pathogenic 
mechanism that results from haploinsufficiency. 
 
4.2 RARE DISORDERS IN CONSANGUINEOUS FAMILIES 
(PAPER/MANUSCRIPT I, III, IV) 
4.2.1 Overall results in the cohort 
A total of 20 families fulfilled the criteria of at least two siblings with the same rare disorder, 
consanguineous parents and normal findings on clinical array-CGH. These were included for 
further studies with detailed phenotypic investigations and WES of affected as well as 
unaffected siblings and parents, followed by a process of filtering and evaluation as described 
in chapter 3. 
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Genetic results 
In 14 out of 20 families, a pathogenic variant causative of the observed phenotype was 
identified. Out of these “solved cases”, 11 families had variants in known disease genes and 3 
families had variants in genes that were not associated to a disease phenotype at the time for 
initial evaluation (PIGT, TFG and KIAA1109). Through functional evaluation and/or 
additional independent cases that were subsequently published, the variants in PIGT, TFG 
and KIAA1109 have proved to be pathogenic and we could thus confirm these genes as novel 
disease genes. In addition, 4 families had variants that were considered as possibly causative 
of their disease phenotype, although causal associations remain to be established. The 
detected pathogenic variants were all present in a homozygous state in the affected 
individuals while heterozygous in their parents and the variants were of various types; 
missense variants (n=6), nonsense variants (n=4), indels or frameshift variants (n=3) and 
large intragenic deletions (n=1) (Table 1). The finding of a homozygous deletion seen in 1 
out of 14 families correlates to recent findings by Boone et al. who analyzed a cohort of 
>20000 individuals and estimated the carrier frequency of heterozygous recessive SNVs to be 
13.5 times higher than the carrier frequency of heterozygous recessive CNVs.54 
Phenotypic results 
The most common presentation among the patients was intellectual disability (ID). On 
detailed clinical assessment, all patients with ID manifested additional features, ranging from 
mild traits such as dysmorphic facial features and abnormalities on biochemical testing to 
severe manifestations like intractable seizures and gross intracranial malformations. In many 
cases, identification of these findings were essential for evaluation of the genetic data from 
WES and proved to be crucial for ascribing pathogenicity to the detected genetic variants and 
reaching a diagnosis for the patient. Six families presented with a phenotype where ID was 
not seen as a main feature; in two families, there were severe disorders with prenatal onset 
and intrauterine or neonatal lethality, another two families were diagnosed with spastic 
paraparesis, one additional family presented a phenotype of severe myopathy and, lastly, one 
family had symptoms compatible with ectodermal dysplasia (Table 1). 
Joint analysis of genotype-phenotype results 
For the 14 families in whom a molecular etiology was established, the majority were affected 
by disorders that have been reported in only a handful of cases, in single families or by 
disorders with no previous patients reported (Table 1). The latter was the case for the family 
in whom a homozygous variant in PIGT was detected. Pathogenicity could be confirmed by 
functional validation, described in more detail below. Two families were affected by 
disorders that had previously been described only in single families. One of these families 
included three fetuses affected by fetal akinesia deformation sequence (FADS) in whom we 
identified a homozygous intragenic deletion (exon 28-55) in KIAA1109. This gene is not yet 
annotated as a disease gene in OMIM, but has recently been suggested as a candidate gene by 
Alazami et al. who identified a variant in KIAA1109 in a family with a phenotype similar to 
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that of our patients.60 The second family was affected by spastic paraplegia and a 
homozygous pathogenic variant in the TFG gene was identified. Bi-allelic disease-causing 
variants in this gene have been previously reported in one family with complicated spastic 
paraplegia.83 
 
Table 1. Results of MPS-analysis and evaluation in the cohort of 20 families 
P, pathogenic variant (causative of the observed disease phenotype) identified; C, candidate gene/s 
identified; -, no candidate gene or pathogenic variant was identified; ID, intellectual disability; HSP, 
hereditary spastic paraparesis; FADS, fetal akinesia deformation sequence; *, numbers indicate how 
many cases have been reported with a pathogenic variant in the same gene and a phenotype that is 
identical or similar to the study case or, in parenthesis, a phenotype that is distinctly different from the 
study case 
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A resemblance in clinical presentation between our patients and previously reported cases 
was true for most, but not all patients with an identified disease-causing variant. In the 
families with pathogenic variants in MAN1B1, RIPK4 and FLVCR2, respectively, the 
observed phenotypes differed in some aspects, compared to the majority of previously 
reported cases. The family with variants in FLVCR2 is described in more detail below.  
For those cases in whom we were not able to establish the molecular etiology with certainty, 
there may be several reasons for this. The disease-causing variant may reside in a genomic 
region that was not captured by the method used. Furthermore, variants may be overlooked 
due to their position in genes for which current knowledge is insufficient regarding gene 
function and phenotypic effects of variants. Considering the families with variants that were 
scored as likely pathogenic, it may be very difficult to prove pathogenicity, partly due to lack 
of additional cases with variants affecting the same gene. Studies in order to evaluate these 
variants are ongoing. Thus, future results and re-evaluation of the data may increase the 
diagnostic yield.  
The diagnostic yield of 70% in this study is comparable to the yield in other similar studies 
that have applied WES in families with several affected individuals and kinship between the 
parents. The yield varies from 36% to 95% between different studies.57-62 One explanation to 
these differences is that some studies have included cases with likely pathogenic variants in 
novel disease genes among the positive cases, while others have only considered cases with 
variants in known disease genes.  
4.2.2 PIGT – a novel disease gene associated to AR syndromic ID  
In one of the families from the cohort described above, there were four patients with the same 
congenital disorder characterized by intellectual disability, hypotonia and seizures, in 
combination with abnormal skeletal and ophthalmologic findings. Results from WES 
identified a homozygous variant, c.547A>C (p.Thr183Pro), in the gene PIGT as the most 
likely disease-causing variant. The predicted protein alteration affects a highly conserved 
amino acid and several prediction programs scored the variant as deleterious (scaled CADD 
score 26). In addition, the variant segregated with the disease on analysis with Sanger 
sequencing of eight family members in total. PIGT encodes phosphatidylinositol-glycan 
biosynthesis class T protein, which is part of the glycosylphosphatidylinositol (GPI) anchor 
pathway. The gene was not previously reported as a disease gene. However, several other 
genes in the same biochemical pathway were associated to disorders with a common core 
phenotype that includes ID, seizures and abnormal levels of alkaline phosphatase – all of 
which were present in the patients from the study family. In order to functionally validate the 
detected variant in PIGT, we wanted to measure the level of GPI-linked proteins on the cell 
surface. This was achieved by flow cytometry, which showed that granulocytes from the 
patients had reduced levels of the GPI-anchored protein CD16b, supporting pathogenicity of 
the variant. Further functional in-vivo validation via morpholino-mediated knockdown of the 
PIGT ortholog in zebrafish (pigt) showed that, unlike human wildtype PIGT mRNA, the 
p.Thr183Pro encoding mRNA failed to rescue gastrulation defects induced by the 
  30 
suppression of pigt. When summarizing the results, we concluded that the detected 
homozygous variant in PIGT was causative of the observed phenotype and thus, PIGT 
represents a novel disease gene associated to syndromic ID. 
Two additional families have subsequently been published85, 86, further confirming PIGT as a 
disease gene, causative of multiple congenital anomalies-hypotonia-seizures syndrome 3 
(MIM 615398). 
4.2.3 Pathogenic variants in FLVCR2 are compatible with survival beyond 
infancy 
In another family from the cohort described above, a brother and a sister were affected by a 
disorder of severe intellectual and neurologic disabilities. They had no functional movements, 
nor any means of communication and they suffered from seizures. Imaging of the brain 
showed calcifications, profound ventriculomegaly with only a thin edging of the cerebral 
cortex and hypoplastic cerebellum. WES revealed, in both patients, a homozygous variant, 
c.1289C>T (p.Thr430Met), in the gene FLVCR2. The variant was predicted to be deleterious 
upon analysis with several prediction programs and pathogenicity was further supported by 
segregation in the family with neither of five healthy members carrying the variant in a 
homozygous state. Additional support of pathogenicity came from a previous report of the 
variant being detected in a compound heterozygous state in a fetus with Fowler syndrome.87 
FLVCR2 is a known disease gene causative of proliferative vasculopathy and 
hydranencephaly-hydrocephaly syndrome (MIM 225790), also known as Fowler syndrome, 
which was previously considered prenatally lethal. The features described in prenatal cases 
are glomerular vasculopathy in the central nervous system, severe hydrocephaly, hypokinesia 
and arthrogryposis. These features and the findings in the study patients are similar. 
However, there is a striking difference in survival which prove that Fowler syndrome is not 
always prenatally lethal, but may be compatible with survival beyond infancy.  
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5 CONCLUDING REMARKS  
The studies in the thesis have focused on determining the molecular etiology for rare 
congenital disorders and delineating the phenotypes associated with these disorders. 
The specific conclusions from the results are summarized below. In brief, the results:  
• Expand the spectrum of pathogenic variants in SATB2 and confirm the presence of a 
distinct and recognizable SATB2-deficiency phenotype 
• Establish PIGT as a novel disease gene 
• Confirm TFG and KIAA1109 as novel disease genes 
• Expand the phenotypic spectrum for disorders associated with variants in MAN1B1, 
RIPK4 and FLVCR2  
• Identify novel candidate genes for congenital disorders 
There are several overall conclusions to be drawn from the studies. First of all, WES is a 
very powerful method for the identification of disease-causing variants in consanguineous 
families. Furthermore, the diversity of AR diseases among these families is enormous with 
many of the identified disorders being extremely rare. An additional conclusion is that a 
detailed phenotypic assessment is crucial for interpretation of data from large-scale genetic 
screening and for ascribing pathogenicity to the identified variants. Moreover, the full 
spectrum of genetic variants, including sequence alterations and CNVs, should be 
considered for the etiology of rare disorders.  
The results altogether add detail to the clinical presentations of the given disorders and 
expand the number of genes and genetic variants with a presumed or established causal 
association to congenital disorders. Ultimately, this may increase the chances to achieve a 
genetic diagnosis for future patients.   
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6 FUTURE PERSPECTIVES 
There are several challenges and also great opportunities for future studies of congenital 
disorders and their etiology. One of the challenges will be to improve the genome wide 
detection rate for different types of genetic variants as well as to improve interpretation of 
these variants. A related future perspective regards potential prevention of congenital 
disorders by carrier screening for couples at increased risk of having a child with an 
autosomal recessive disorder or by prenatal screening for pathogenic de novo variants and 
the interpretation of variants detected. A further important field of research that may 
expand in the future concerns understanding of the molecular pathomechanisms behind 
these disorders and development of treatment options.  
Improved detection rates for common genetic variants (SNVs, indels and CNVs) 
Despite the advances in technology over the last years and the increase in diagnostic yield 
for patients with rare disorders, there is still a large proportion of the patients in whom the 
etiologic diagnosis remains unknown.22 By applying WGS instead of WES, the diagnostic 
yield increases significantly. For a population of patients in whom no etiology was 
established by a combination of micro-array and WES, the molecular etiology could be 
identified in 42% by WGS. The etiologies detected by WGS were small CNVs (38% of the 
diagnosed cases) and SNVs/small indels in coding regions (62% of the diagnosed cases).21 
In other words, some of the pathogenic variants in coding regions are missed by WES and 
small CNVs are difficult to detect on micro-array or WES. If cost was not an issue, WGS 
would therefore be the method of choice in both research and clinical setting. In the future, 
costs are likely to drop, enabling a more widespread use of WGS. 
Detection of “alternative” genetic variants and mechanisms  
Even with an improved detection rate of SNVs, small indels and CNVs in coding regions of 
the genome, there is still a proportion (30-40%) of the rare disease patients in whom an 
etiologic diagnosis can not be established. Some of these disorders may be caused by 
alternative types of genetic variants and mechanisms while others may be due to any 
genetic variant that escape recognition or pathogenicity establishment because of currently 
insufficient data for interpretation.  
Genome wide screening for alternative variants or mechanisms include search for somatic 
mosaicism, variants in non-coding regions of the genome, balanced structural variants, 
repeat expansions, epigenetic aberrations such as imprinting defects and uniparental disomy 
(UPD). For some of these, there are numbers on their frequency in cohorts of patients with 
congenital disorders, e.g. mosaicism for CNVs in 0.5-2% of the patients19, 88 and UPD in 
<1% of the patients19. A recently described mechanism for disease is structural variants that 
disrupt certain regions called topologically associated domains (TADs). These domains can 
be regarded as regulatory units within which enhancers and promoters can interact. 
Disruption of a TAD can lead to altered gene-expression and thereby cause disease.89 
  33 
Development of methods, including bioinformatic methods, to detect all of these variants, 
interpret them (see below) and determine their relative contribution to the etiology of rare 
disorders are ongoing and will be an important future field of research. 
Improved interpretation of genetic variants 
Another future challenge, in addition to detecting all types of genetic variants, is 
interpreting these variants and establishing a causal relation to a specific disease phenotype. 
This applies to both research and clinical settings. Major challenges concern interpretation 
of variants in non-coding regions of the genome including variants that affect genomic 
structure and transcription as well as understanding the interaction between several co-
occurring variants and their common contribution to a specific phenotype. 
Also for variants that intuitively are easier to grasp, like those within genes, there are 
challenges in prioritization among a number of variants and interpretation. Further 
development and use of databases may facilitate this process and improve the outcome. 
Some of the existing databases have a function of finding other patients based on 
phenotypic and/or genotypic similarities and this may become increasingly important for 
interpreting variants and understanding rare disorders. Furthermore, “phenotype-programs” 
are emerging, which use input regarding the patient’s phenotype, either for prioritization of 
variants detected by MPS or for assessment of a candidate gene’s relevance to the 
phenotype observed in a patient.90 
Genetic screening for couples at increased risk of having a child with an AR disorder 
Pre-conception carrier screening by MPS for consanguineous couples is in theory a good 
method for identifying common recessive disease alleles. This would enable individualized 
genetic counseling and more accurate figures regarding the risk of having a child with an 
AR disorder as well as enable prenatal diagnostics or preimplantation genetic diagnosis 
(PGD) for couples at high (25%) risk. However, as of today there may be difficulties in 
applying this method in a clinical setting, much due to insufficient knowledge about the full 
spectrum of AR disorders and interpretation of genetic variants. These issues may lead to 
false negative results and, worse, false positive results if a variant is misinterpreted as 
pathogenic. As mentioned in previous chapters, seemingly deleterious variants may prove 
to be benign and variants in disease databases may sometimes be incorrectly annotated as 
pathogenic.91 Large studies to address the clinical feasibility of pre-conception carrier 
screening by MPS has not yet been performed. The current issues of false negative and 
false positive rates may decrease in the future, opening up for such studies. 
Prenatal screening for pathogenic de novo variants 
In theory, prenatal screening with MPS in order to detect pathogenic de novo variants 
would enable prevention of many congenital disorders. The issues (ethical issues not 
included) with this method are similar to those described above with false negative and 
false positive results. In addition, the time frame is much shorter in the case of prenatal 
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screening. Common to all types of prospective genetic screening is the lack of a phenotype 
to aid in the interpretation of the genetic variants detected. Despite these issues, studies to 
explore the opportunities with this type of screening may be undertaken in the future. 
Treatment of rare disorders  
Only small fractions of the rare disorders are treatable today. Recent years’ progress in 
deciphering the etiology for rare genetic disorders will hopefully be followed by 
advancements in understanding of the pathophysiology that underlie these disorders and 
ultimately development of treatments in the future. However, this is a challenging task, not 
only due to difficulties in understanding the biology, but also due to issues regarding 
financing and clinical trials, which in turn is a consequence of the rarity of these disorders.  
Future perspectives and reflections on “genotype versus phenotype”  
Medical research is often focused on understanding human disease and the development of 
treatments. In a clinical setting, treatment and care largely depend on the specific 
disorder/diagnosis. Therefore, questions of relevance for both research and clinical care are 
how we define a disorder and how we establish a specific diagnosis in a patient (in order to 
choose the most effective treatment and care, give correct information on prognosis etc.).  
Regarding genetic disorders, the answers to these questions are now shifting from “by the 
phenotype” to “by the genotype”. With new technologies, such as MPS, that enables us to 
define many of these disorders based on the etiology, these questions are more relevant than 
ever before. The relevance is not restricted to rare disorders, but also applies to what we 
usually denote as common disorders. Many of the common disorders have traditionally been 
defined based on their phenotype, e.g. diabetes, cancer and schizophrenia. As of today and for 
the future, some of these disorders will rather be defined by their etiology. Data from genome 
wide screening studies has proved that many common disorders have a heterogeneous 
etiology and are actually collections of rare disorders. What is learned from studies of rare 
disorders may thus be applicable also to common disorders. These findings lead to another 
question of how much breakdown into etiological subgroups that is feasible in a clinical 
setting and for treatment development. Is definition of a disorder by a specific gene (or genes) 
enough, or should the exact genetic variant be considered, or even the exact variant in the 
context of n additional factors? At the extreme end, this would mean that each patient has a 
unique disorder that may require unique care and treatment. This may bring us to a new era 
of ‘personalized medicine’ with influences on care and treatments for both rare and 
common disorders. 
What about the phenotype? If diagnosis, care and treatment will be based on the genotype, 
is there no need to define a phenotype for future patients with genetic disorders? Most 
likely, clinical assessment of patients will be just as important in the future as it was 
previously. However, there will probably be (and already is) a shift in the way phenotypic 
data is used for establishing a diagnosis in patients. Historically, time and money were spent 
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on gathering clinical information that could be used to group patients together, sometimes 
followed by targeted genetic analyses, in order to establish a diagnosis. As of today and in the 
future, clinical data may instead be used to facilitate the interpretation of variants generated 
by genomic screening methods, to achieve a diagnosis. Targeted genetic analyses based on an 
extensive phenotype would thereby be replaced by targeted clinical investigations based on 
an extensive genetic analysis.  
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7 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Medfödda sjukdomar, skador eller funktionsnedsättningar drabbar ca 3-4% av alla födda 
barn. Vissa diagnoser märks redan i fosterlivet medan andra upptäcks först efter födslen 
eller längre fram. De är ofta förknippade med kroniska symptom och en betydande 
inverkan på livet för drabbade individer och deras familjer. Vanligt förekommande 
symptom är olika typer av missbildningar och/eller utvecklingsstörning. Detta förekommer 
dock inte hos alla, utan vissa individer kan ha andra typer av symptom såsom allvarlig 
muskelsvaghet, blindhet, dövhet etc. De flesta av diagnoserna är sällsynta (<1/2000) medan 
andra, som till exempel Down syndrom, är vanligare. Man har uppskattat att det finns 
närmare 10.000 sällsynta diagnoser, vilket innebär att varje enskild diagnos drabbar få 
individer, ibland bara en handfull personer i hela världen. Kunskapen är därför begränsad 
vad gäller många av dessa diagnoser. Orsaken är ofta genetisk, men även andra faktorer 
såsom infektioner, läkemedel och skadliga ämnen under eller efter fosterlivet samt 
autoimmunitet kan ge upphov till medfödda eller tidigt debuterande sjukdomar. 
Forskningen kring dessa diagnoser och deras orsaker har avancerat snabbt under de senaste 
tio åren. Vad gäller utvecklingsstörning till exempel har det visats att upp till 70% av 
patienterna har detta på grund av en genetisk orsak. Det finns olika typer av genetiska 
förändringar som kan orsaka sjukdom och i fallen med utvecklingsstörning sågs hos ca 
10% en kromosom-avvikelse (tex en extra kromosom 21 som vid Down syndrom), hos ca 
20% små avvikelser i mängden arvsmassa och hos ca 40% enstaka “stavfel” i den genetiska 
koden. De sistnämnda två benämns kopietals-varianter (copy number variants, CNVs) 
respektive enbaspars-varianter (single nucleotide variants, SNVs). Vidare har man sett att 
hos de flesta individerna hade den genetiska förändringen uppstått de novo, vilket innebär 
att den inte var nedärvd från föräldrarna utan sågs bara hos individen själv.  
Många av de medfödda sjukdomarna beror dock på genetiska förändringar som ärvs från 
båda föräldrarna via så kallad autosomalt recessiv (AR) nedärvning. Dessa sjukdomar 
förekommer över hela världen och kan drabba alla, men är ofta väldigt sällsynta, vilket kan 
förklara varför man inte fann så många AR sjukdomar i gruppen med utvecklingsstörning. 
Om man fått ett barn med en AR sjukdom är risken 25% att eventuella framtida syskon 
drabbas av samma sjukdom. Fullständig kunskap om dessa sjukdomar saknas, men är viktig 
ur flera aspekter - inte minst för att kunna fastställa en korrekt diagnos och därmed erbjuda 
rätt information och vård till drabbade individer och deras föräldrar samt för att kunna 
erbjuda fosterdiagnostik eller andra alternativ för de som så önskar. AR sjukdomar är mer 
frekventa i vissa regioner, till exempel regioner som varit geografiskt isolerade, eller då det 
finns släktskap mellan föräldrarna, men även i dessa fall är förekomsten låg (ca 2-4%).  
Syftet med studierna i avhandlingen har varit att undersöka och fastställa den genetiska 
bakgrunden till olika sällsynta sjukdomar med fokus på AR sjukdomar samt att undersöka 
och beskriva den kliniska bilden vid dessa sjukdomar.  
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I studierna har totalt 21 familjer med barn som drabbats av en medfödd sjukdom genomgått 
undersökning. Majoriteten av familjerna (20 st) inkluderades på basen av en mycket stark 
misstanke om AR sjukdom. Denna misstanke grundades på förekomst av minst två barn 
med samma symptombild i familjen samt släktskap mellan föräldrarna. Dessutom 
studerades ytterligare en familj med en sällsynt de novo CNV. 
De drabbade individerna har dels genomgått en noggrann klinisk undersökning för att 
fastställa vilka symptom de har samt dels flera genetiska undersökningar och ibland 
ytterligare uppföljande undersökningar. De genetiska undersökningar har inneburit att 
arvsmassan har analyserats för att identifiera genetiska förändringar av de typer som 
nämnts ovan (kromosomavvikelser, CNVs och SNVs). Inom ramen för sjukvården har sk 
array-CGH utförts, vilken kan detektera de två förstnämnda typerna av förändringar. 
Därefter har komplettering skett med helexomsekvensering, vilket innebär att DNA-
sekvensen i alla gener “läses av” och olika “stavfel” kan detekteras. Vid båda metoderna 
jämförs arvsmassan med ett “facit” från en eller några friska individer. Arvsmassan är till 
98-99% identisk om man jämför två individer, medan 1-2% av arvsmassan naturligt skiljer 
sig åt mellan individerna. En frisk individ har ca 30000 “stavfel” (SNVs) i sina gener och 
totalt ca 1000 CNVs om man jämför med ett “facit” från en annan frisk individ, vilket 
innebär att de förändringar som ses hos en drabbad individ inte alls behöver vara orsaken 
till sjukdomen utan bara en normalvariant som inte finns hos just den eller de individer som 
“facit” baseras på. Att skilja mellan genetiska normalvarianter och sjukdomsorsakande 
varianter är en av de största utmaningarna inom både genetik-forskning och sjukvård. I 
studierna har detta gjorts genom bland annat användande av databaser för att filtrera bort 
kända normalvarianter, jämförelse av arvsmassan från andra familjemedlemmar 
(framförallt syskon med eller utan sjukdom) samt jämförelse av den kliniska bilden mot 
vad som finns känt sedan tidigare om den gen som kan vara skadad. I utvalda fall har 
kompletterande undersökningar bidragit till att fastställa om förändringen varit orsaken till 
sjukdom eller ej. 
Resultaten av dessa undersökningar ledde till att man i 15 av de 21 familjerna kunde 
fastställa sjukdomsorsaken och rapportera detta tillbaka till familjen och sjukvården. I 
endast tre av familjerna var den påvisade sjukdomen en relativt välbeskriven sjukdom med 
över femtio olika fall beskrivna i världen. Resten av familjerna visade sig vara drabbade av 
mycket sällsynta sjukdomar. Ytterligheten var en familj med flera barn drabbade av svår 
utvecklingsförsening och epilepsi där en genetisk variant i genen PIGT detekterades. Att 
denna variant var sjukdomsorsakande kunde bekräftas med en rad olika analyser. Dessa fall 
var de första beskrivna i världen med “PIGT-sjukdom”. Idag finns ytterligare ett par 
familjer rapporterade med samma sjukdom som nu kallas “multiple congenital anomalies-
hypotonia-seizures syndrome-3 (MCAHS3)”. I två andra studie-familjer fastställdes 
diagnoser som endast beskrivits en gång tidigare. Med resultaten från denna studie kan 
orsaken till dessa två allvarliga sjukdomar bekräftas samt den kliniska bilden ytterligare 
beskrivas. Beskrivning av den kliniska bilden är värdefull i de flesta fall av dessa sällsynta 
sjukdomar. För de flesta av studie-patienterna stämde den kliniska bilden väl med de få fall 
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som beskrivits tidigare, medan individer från tre av familjerna uppvisade en “icke-klassisk” 
symptombild. Det mest påtagliga fallet rörde en familj med två syskon som hade svår 
utvecklingsstörning samt stora avvikelser på hjärnröntgen där man bland annat såg kraftigt 
vidgade hålrum. Diagnosen som fastställdes, Fowler syndrom, hade tidigare beskrivits 
endast hos foster och ansetts icke-förenlig med överlevnad. Trots sin svåra sjukdom är 
äldsta syskonet nu sju år gammal. Slutligen, för den studie-familj som inte hade en AR 
sjukdom utan istället en sällsynt de novo CNV visade resultaten att det rörde sig om en 
dubblering av arvsmassa inom genen SATB2. Denna gen är kopplad till en specifik diagnos 
med bland annat gomspalt och utvecklingsstörning. Nytt i detta fall var att den här typen av 
förändring inte rapporterats bland något av de få tidigare fallen (som istället hade små 
“stavfel” eller förlust av arvsmassa inom samma gen). 
De övergripande slutsatserna från studierna är att helexomsekvensering är en mycket 
effektiv metod för identifiering av sjukdomsorsakande genetiska varianter i familjer med 
stark misstanke om AR sjukdom samt att en noggrann klinisk undersökning i många fall är 
avgörande för att kunna tolka resultaten från de genetiska undersökningarna. En ytterligare 
slutsats är att analys av samtliga typer av genetiska varianter, inklusive SNVs och CNVs, 
bör ingå vid diagnostik av sällsynta sjukdomar. 
Resultaten från denna studie har breddat kunskapen om den kliniska bilden vid de 
diagnoser som beskrivits samt utökat antalet gener och genetiska varianter som har 
betydelse för uppkomsten av medfödda sjukdomar. Förhoppningsvis kan detta bidra till att 
öka chansen för framtida patienter att erhålla en diagnos och därmed förbättra deras och 
familjernas vård och omhändertagande. 
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